Search

Your search keyword '"Yedilbayev, Askar"' showing total 37 results
Start Over Author "Yedilbayev, Askar"

Refine your results

more »

more »

more »

more »
37 results on '"Yedilbayev, Askar"'

2. Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan

Author

Rashitov, Makhmujan, primary, Franke, Molly, additional, Trevisi, Letizia, additional, Bekbolatova, Gulzhanat, additional, Shalimova, Julia, additional, Eshmetov, Gafurzhan, additional, Bektasov, Sagit, additional, LaHood, Allison, additional, Arlyapova, Nataliya, additional, Osso, Elna, additional, Yedilbayev, Askar, additional, Korotych, Oleksandr, additional, Ciobanu, Anisoara, additional, Skrahina, Alena, additional, Mitnick, Carole D, additional, Seung, Kwonjune, additional, Algozhin, Yerkebulan, additional, and Rich, Michael L, additional

Published
2024
Full Text
View/download PDF

10. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region

Author

Baggaley, Rebecca F, primary, Nazareth, Joshua, additional, Divall, Pip, additional, Pan, Daniel, additional, Martin, Christopher A, additional, Volik, Mikhail, additional, Seguy, Nicole S, additional, Yedilbayev, Askar, additional, Reinap, Marge, additional, Vovc, Elena, additional, Mozalevskis, Antons, additional, Dadu, Andrei, additional, Waagensen, Elisabeth, additional, Kruja, Krista, additional, Sy, Tyrone Reden, additional, Nellums, Laura, additional, and Pareek, Manish, additional

Published
2022
Full Text
View/download PDF

11. Diagnostic Capacities for Multidrug-Resistant Tuberculosis in the World Health Organization European Region

Author

Maurer, Florian P., primary, Shubladze, Natalia, additional, Kalmambetova, Gulmira, additional, Felker, Irina, additional, Kuchukhidze, Giorgi, additional, Köser, Claudio U., additional, Cirillo, Daniela Maria, additional, Drobniewski, Francis, additional, Yedilbayev, Askar, additional, Ehsani, Soudeh, additional, Avellón, Ana, additional, Chulanov, Vladimir, additional, Maurer, Florian P., additional, Niemann, Stefan, additional, Noroc, Ecaterina, additional, Paredes, Roger, additional, Simões, Daniel, additional, Skrahina, Alena, additional, and Stanojevic, Maja, additional

Published
2022
Full Text
View/download PDF

12. Integrated use of laboratory services for multiple infectious diseases in the WHO European Region during the COVID-19 pandemic and beyond

Author

Simões, Daniel, Ehsani, Soudeh, Stanojevic, Maja, Shubladze, Natalia, Kalmambetova, Gulmira, Paredes, Roger, Cirillo, Daniela Maria, Avellón, Ana, Felker, Irina, Maurer, Florian P, Yedilbayev, Askar, Drobniewski, Francis, Vojnov, Lara, Johansen, Anne S, Seguy, Nicole, Dara, Masoud, European Laboratory Initiative on TB, HIV and viral hepatitis core group members, Fundação para a Ciência e Tecnologia (Portugal), Unión Europea. Fondo Social Europeo (ESF/FSE), Imperial College Trust, Commission of the European Communities, and Research England

Subjects
laboratory services, European Laboratory Initiative on TB, HIV and viral hepatitis core group members, Epidemiology, Public Health, Environmental and Occupational Health, Integration, Sexually Transmitted Diseases, viral hepatitis, HIV, COVID-19, integration, HIV Infections, World Health Organization, Hepatitis C, 1117 Public Health and Health Services, Virology, Laboratory services, Sexually transmitted infections, Humans, Tuberculosis, Viral hepatitis, Pandemics, sexually transmitted infections, 0605 Microbiology, 1199 Other Medical and Health Sciences
Abstract

Technical advances in diagnostic techniques have permitted the possibility of multi-disease-based approaches for diagnosis and treatment monitoring of several infectious diseases, including tuberculosis (TB), human immunodeficiency virus (HIV), viral hepatitis and sexually transmitted infections (STI). However, in many countries, diagnosis and monitoring, as well as disease response programs, still operate as vertical systems, potentially causing delay in diagnosis and burden to patients and preventing the optimal use of available resources. With countries facing both human and financial resource constraints, during the COVID-19 pandemic even more than before, it is important that available resources are used as efficiently as possible, potential synergies are leveraged to maximise benefit for patients, continued provision of essential health services is ensured. For the infectious diseases, TB, HIV, hepatitis C (HCV) and STI, sharing devices and integrated services starting with rapid, quality-assured, and complete diagnostic services is beneficial for the continued development of adequate, efficient and effective treatment strategies. Here we explore the current and future potential (as well as some concerns), importance, implications and necessary implementation steps for the use of platforms for multi-disease testing for TB, HIV, HCV, STI and potentially other infectious diseases, including emerging pathogens, using the example of the COVID-19 pandemic. Daniel Simões was the recipient of PhD grant PD/BD/128008/2016 from Fundação para a Ciência e Tecnologia (FCT), co-funded by the “Programa Operacional Capital Humano/Fundo Social Europeu” (POCH/FSE). The funder did not have any role in manuscript preparation, revision or submission. Sí

Published
2022

13. Corrigendum to ‘Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis’ International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95

Author

Maretbayeva, Shynar M., primary, Rakisheva, Anar S., additional, Adenov, Malik M., additional, Yeraliyeva, Lyazzat T., additional, Algozhin, Yerkebulan Zh., additional, Stambekova, Assel T., additional, Berikova, Elmira A., additional, Yedilbayev, Askar, additional, Rich, Michael L., additional, Seung, Kwonjune J., additional, and Issayeva, Assiya M., additional

Published
2022
Full Text
View/download PDF

17. suNational policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for migrants among Member States of the WHO European Region.

Author

Baggaley, Rebecca F, Nazareth, Joshua, Divall, Pip, Pan, Daniel, Martin, Christopher A, Volik, Mikhail, Seguy, Nicole S, Yedilbayev, Askar, Reinap, Marge, Vovc, Elena, Mozalevskis, Antons, Dadu, Andrei, Waagensen, Elisabeth, Kruja, Krista, Sy, Tyrone Reden, Nellums, Laura, and Pareek, Manish

Subjects
HEPATITIS B, REFUGEE services, GOVERNMENT policy, HIV, TUBERCULOSIS
Abstract

Rationale for review.Migrants to the WHO European Region are disproportionately affected by infections including tuberculosis, HIV and hepatitis B and C (HBV/HCV), compared with the host population. There are inequities in the accessibility and quality of health services available to refugees and migrants in the Region. This has consequences for health outcomes and will ultimately impact the ability to meet Regional infection elimination targets. We reviewed academic and grey literature to identify national policies and guidelines for tuberculosis/HIV/HBV/HCV specific to migrants in Member States of the WHO European Region, and identify: a) evidence informing policy and b) barriers and facilitators to policy implementation.Key Findings: Relatively few primary national policy/guideline documents were identified that related to migrants and tuberculosis (14 of 53 Member States (26%), HIV (n = 15, 28%) and HBV/HCV (n = 3, 6%), which often did not align with WHO recommendations and for some countries, violated migrants' human rights. We found extreme heterogeneity in the implementation of WHO- and European Centre for Disease Prevention and Control-advocated policies and recommendations on the prevention, diagnosis, treatment and care of TB/HIV/HBV/HCV infection in migrants across Member States of the WHO European Region.There is great heterogeneity in implementation of WHO- and European Centre for Disease Prevention and Control-advocated policies on the prevention, diagnosis, treatment and care of TB/HIV/HBV/HCV infection in migrants across Member States in the Region.Conclusions/recommendations: More transparent and accessible reporting of national policies and guidelines are required, together with the evidence base upon which these policy decisions are based. Political engagement is essential to drive changes in national legislation to ensure equitable and universal access to diagnosis and care for infectious diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Factors Associated with Unfavourable Treatment Outcomes in Patients with Tuberculosis: A 16-Year Cohort Study (2005–2020), Republic of Karakalpakstan, Uzbekistan

Author

Gadoev, Jamshid, primary, Asadov, Damin, additional, Harries, Anthony D., additional, Kumar, Ajay M. V., additional, Boeree, Martin Johan, additional, Hovhannesyan, Araksya, additional, Kuppens, Lianne, additional, Yedilbayev, Askar, additional, Korotych, Oleksandr, additional, Hamraev, Atadjan, additional, Kudaybergenov, Kallibek, additional, Abdusamatova, Barno, additional, Khudanov, Bakhtinur, additional, and Dara, Masoud, additional

Published
2021
Full Text
View/download PDF

22. Impact of the COVID-19 pandemic on tuberculosis national reference laboratory services in the WHO European Region, March to November 2020

Author

Maurer, Florian P, Shubladze, Natalia, Kalmambetova, Gulmira, Felker, Irina, Kuchukhidze, Giorgi, Drobniewski, Francis, Yedilbayev, Askar, Ehsani, Soudeh, Avellón, Ana, Baydulloeva, Zamira, Chulanov, Vladimir, Cirillo, Daniela Maria, Kireev, Dmitry, Köser, Claudio U, Niemann, Stefan, Noroc, Ecaterina, Paredes, Roger, Schuurman, Rob, Sevastyanova, Elina V, Simões, Daniel, Skrahina, Alena, Stanojevic., Maja, and German Government

Subjects
Tuberculosis, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Reference laboratory, World Health Organization, 1117 Public Health and Health Services, 03 medical and health sciences, 0302 clinical medicine, COVID-19 Testing, Tuberculosis diagnosis, Virology, Environmental health, Pandemic, diagnostics, Medicine, Humans, 030212 general & internal medicine, Diagnostics, Pandemics, business.industry, SARS-CoV-2, Public Health, Environmental and Occupational Health, COVID-19, Workload, European region, medicine.disease, PCR, 030228 respiratory system, business, Laboratories, European Laboratory Initiative on TB, HIV and Viral Hepatitis, Rapid Communication, Additional members of the European Laboratory Initiative on TB, HIV and Viral Hepatitis core group (in alphabetical order), 0605 Microbiology, 1199 Other Medical and Health Sciences
Abstract

We assessed the impact of COVID-19 on diagnostic services for tuberculosis (TB) by national reference laboratories in the WHO European Region. Of 35 laboratories, 30 reported declines in TB sample numbers, amounting up to > 50% of the pre-COVID-19 volumes. Sixteen reported reagent or consumable shortages. Nineteen reallocated ressources to SARS-CoV-2 testing, resulting in an overall increase in workload, largely without a concomitant increase in personnel (n = 14). This poses a risk to meeting the 2025 milestones of the End TB Strategy. Financial support for this work has been provided by the German Government. Sí

Published
2021

25. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18

Author

Auchynka, Vera, primary, Kumar, Ajay M.V., additional, Hurevich, Hennadz, additional, Sereda, Yuliia, additional, Solodovnikova, Varvara, additional, Katovich, Dzmitry, additional, Setkina, Svetlana, additional, Yedilbayev, Askar, additional, Skrahin, Aliaksandr, additional, and Skrahina, Alena, additional

Published
2021
Full Text
View/download PDF

26. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19

Author

Solodovnikova, Varvara, primary, Kumar, Ajay M.V., additional, Hurevich, Hennadz, additional, Sereda, Yuliia, additional, Auchynka, Vera, additional, Katovich, Dzmitry, additional, Klimuk, Dzmitry, additional, Skrahin, Aliaksandr, additional, Setkina, Svetlana, additional, Charnysh, Iryna, additional, Yedilbayev, Askar, additional, and Skrahina, Alena, additional

Published
2021
Full Text
View/download PDF

28. ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package

Author

Achar, Jay, Bhatia, Vineed, Bloom, Amy, Campbell, Jonathon, Chadha, Sarabjit, Dara, Masuc, Dadu, Andrei, Falzon, Dennis, Fielding, Katherine, Furin, Jennifer, Gebhard, Agnes, Ho, Christine, Jaramillo, Ernesto, Koppelaar, Igne, Hill, Jeremy, Idrissova, Maria, Livchits, Viktoriya, Lönnroth, Knut, Masini, Tiziana, Mirzayev, Fuad, Mitnick, Carole, Monedero, Ignacio, Morishita, Fukushi, Muhammad, Asif, Mukadi, YaDiul, Otami Del Barrio, Mariam, Piubello, Alberto, Rosu, Laura, Scardigli, Anna, Serdiuk, Kseniia, Squire, Bertie, Tiemersma, Edine, Tomeny, Ewan, Yassin, Mohammed, Yedilbayev, Askar, Verkuijl, Sabine, Wandwalo, Eliud, Wares, Fraser, and Zignol, Matteo

Subjects
wf_360, wf_200, wf_310, wf_600
Abstract

TDR in close collaboration with the Global TB Programme at WHO and technical partners the WHO Global TB Programme is leading the development of ShORRT (Short, all-Oral Regimens For Rifampicin-resistant Tuberculosis), an operational research package to assess the effectiveness, safety, feasibility, acceptability, cost and impact (including on health-related quality of life) of the use of all-oral shorter drug regimens for adults and children with MDR/RR-TB.

Published
2019

30. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis

Author

Seung, Kwonjune J, primary, Khan, Palwasha, additional, Franke, Molly F, additional, Ahmed, Saman, additional, Aiylchiev, Stalbek, additional, Alam, Manzur, additional, Putri, Fauziah Asnely, additional, Bastard, Mathieu, additional, Docteur, Wisny, additional, Gottlieb, Gary, additional, Hewison, Catherine, additional, Islam, Shirajul, additional, Khachatryan, Naira, additional, Kotrikadze, Tinatin, additional, Khan, Uzma, additional, Kumsa, Andargachew, additional, Lecca, Leonid, additional, Tassew, Yoseph Melaku, additional, Melikyan, Nara, additional, Naing, Ye Yint, additional, Oyewusi, Lawrence, additional, Rich, Michael, additional, Wanjala, Stephen, additional, Yedilbayev, Askar, additional, Huerga, Helena, additional, and Mitnick, Carole D, additional

Published
2019
Full Text
View/download PDF

31. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

Author

Borisov, Sergey, primary, Danila, Edvardas, additional, Maryandyshev, Andrei, additional, Dalcolmo, Margareth, additional, Miliauskas, Skaidrius, additional, Kuksa, Liga, additional, Manga, Selene, additional, Skrahina, Alena, additional, Diktanas, Saulius, additional, Codecasa, Luigi Ruffo, additional, Aleksa, Alena, additional, Bruchfeld, Judith, additional, Koleva, Antoniya, additional, Piubello, Alberto, additional, Udwadia, Zarir Farokh, additional, Akkerman, Onno W., additional, Belilovski, Evgeny, additional, Bernal, Enrique, additional, Boeree, Martin J., additional, Cadiñanos Loidi, Julen, additional, Cai, Qingshan, additional, Cebrian Gallardo, Jose Joaquín, additional, Dara, Masoud, additional, Davidavičienė, Edita, additional, Forsman, Lina Davies, additional, De Los Rios, Jorge, additional, Denholm, Justin, additional, Drakšienė, Jacinta, additional, Duarte, Raquel, additional, Elamin, Seifeldin Eltaeb, additional, Escobar Salinas, Nadia, additional, Ferrarese, Maurizio, additional, Filippov, Alexey, additional, Garcia, Ana, additional, García-García, José-María, additional, Gaudiesiute, Ieva, additional, Gavazova, Blagovesta, additional, Gayoso, Regina, additional, Gomez Rosso, Roscio, additional, Gruslys, Vygantas, additional, Gualano, Gina, additional, Hoefsloot, Wouter, additional, Jonsson, Jerker, additional, Khimova, Elena, additional, Kunst, Heinke, additional, Laniado-Laborín, Rafael, additional, Li, Yang, additional, Magis-Escurra, Cecile, additional, Manfrin, Vinicio, additional, Marchese, Valentina, additional, Martínez Robles, Elena, additional, Matteelli, Alberto, additional, Mazza-Stalder, Jesica, additional, Moschos, Charalampos, additional, Muñoz-Torrico, Marcela, additional, Mustafa Hamdan, Hamdan, additional, Nakčerienė, Birutė, additional, Nicod, Laurent, additional, Nieto Marcos, Magnolia, additional, Palmero, Domingo Juan, additional, Palmieri, Fabrizio, additional, Papavasileiou, Apostolos, additional, Payen, Marie-Christine, additional, Pontarelli, Agostina, additional, Quirós, Sarai, additional, Rendon, Adrian, additional, Saderi, Laura, additional, Šmite, Agnese, additional, Solovic, Ivan, additional, Souleymane, Mahamadou Bassirou, additional, Tadolini, Marina, additional, van den Boom, Martin, additional, Vescovo, Marisa, additional, Viggiani, Pietro, additional, Yedilbayev, Askar, additional, Zablockis, Rolandas, additional, Zhurkin, Dmitry, additional, Zignol, Matteo, additional, Visca, Dina, additional, Spanevello, Antonio, additional, Caminero, José A., additional, Alffenaar, Jan-Willem, additional, Tiberi, Simon, additional, Centis, Rosella, additional, D'Ambrosio, Lia, additional, Pontali, Emanuele, additional, Sotgiu, Giovanni, additional, and Migliori, Giovanni Battista, additional

Published
2019
Full Text
View/download PDF

33. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB

Author

Ahmad Khan, Faiz, primary, Gelmanova, Irina Y., additional, Franke, Molly F., additional, Atwood, Sidney, additional, Zemlyanaya, Nataliya A., additional, Unakova, Irina A., additional, Andreev, Yevgeniy G., additional, Berezina, Valentina I., additional, Pavlova, Vera E., additional, Shin, Sonya S., additional, Yedilbayev, Askar B., additional, Becerra, Mercedes C., additional, and Keshavjee, Salmaan, additional

Published
2016
Full Text
View/download PDF

35. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.

Author

Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, and Yedilbayev A

Abstract

Background: In 2020, WHO guidelines prioritised the use of a standard fully oral short treatment regimen (STR) consisting of bedaquiline, levofloxacin or moxifloxacin, ethionamide, ethambutol, high-dose isoniazid, pyrazinamide, and clofazimine for the management of rifampicin-resistant tuberculosis. A high prevalence of resistance to constituent drugs precluded its widespread use by countries in the WHO European region. We evaluated three 9-month fully oral modified STRs (mSTRs) in which ethionamide, ethambutol, isoniazid, and pyrazinamide were replaced by linezolid, cycloserine, or delamanid (or a combination)., Methods: This multicountry, prospective, single-arm, cohort study examined the effectiveness and safety of mSTRs for fluoroquinolone-susceptible, rifampicin-resistant pulmonary tuberculosis in 13 countries in the WHO European region during 2020-23. We enrolled adults and children of all ages with bacteriologically confirmed rifampicin-resistant, fluoroquinolone-susceptible pulmonary tuberculosis, and children (aged 0-18 years) with clinically diagnosed disease and a confirmed contact with rifampicin-resistant, fluoroquinolone-susceptible tuberculosis. Participants aged 6 years or older received one of two regimens: bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine; or bedaquiline, linezolid, levofloxacin, clofazimine, and delamanid. Children younger than 6 years received delamanid, linezolid, levofloxacin, and clofazimine. Participants were followed up for 12 months after successful treatment completion to detect recurrence and death. The primary outcome was the cumulative probability of not having an unsuccessful study outcome (defined as treatment failure, on-treatment loss to follow-up, death, or recurrence) before 22 months of study follow-up. The primary safety outcome was the incidence of each adverse event of interest (peripheral neuropathy, optic neuritis, myelosuppression, hepatitis, prolonged QT interval, hypokalaemia, and acute kidney injury) of grade 3 or higher severity during the treatment course., Findings: Between Aug 28, 2020 and May 26, 2021, 7272 patients were screened and 2636 were included in the treatment cohort. 1966 (74·6%) were male, 670 (25·4%) were female, and median age was 43 years (IQR 33-53). Treatment success was recorded for 2181 (82·7%) participants. The cumulative probability of not having an unsuccessful study outcome 22 months after treatment initiation was 79% (95% CI 78-81). Increasing age (adjusted hazard ratio 2·61 [95% CI 1·70-4·04] for people aged >64 years vs 35-44 years), HIV-positive status (1·53 [1·16-2·01]), presence of bilateral cavities (1·68 [1·29-2·19]), smoking history (1·34 [1·05-1·71]), baseline anaemia (1·46 [1·15-1·86]), unemployment (1·37 [1·04-1·80]), elevated baseline liver enzymes (1·40 [1·13-1·73]), and excessive alcohol use (1·47 [1·14-1·89]) were positively associated with unsuccessful study outcomes. In the safety cohort of 2813 participants who received at least one dose, 301 adverse events of interest were recorded in 252 (9·0%) participants with the most frequent being myelosuppression (139 [4·9%] participants, 157 [52·2%] events)., Interpretation: The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for alternative options., Funding: The Global Fund to Fight AIDS, Tuberculosis and Malaria; United States Agency for International Development; Government of Germany; and WHO., Translation: For the Russian translation of the abstract see Supplementary Materials section., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2024 World Health Organization. Published by Elsevier Ltd. All rights reserved. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.)

Published
2024
Full Text
View/download PDF

36. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region.

Author

Baggaley RF, Nazareth J, Divall P, Pan D, Martin CA, Volik M, Seguy NS, Yedilbayev A, Reinap M, Vovc E, Mozalevskis A, Dadu A, Waagensen E, Kruja K, Sy TR, Nellums L, and Pareek M

Subjects
Humans, HIV, Policy, World Health Organization, Refugees, Transients and Migrants, Tuberculosis epidemiology, Hepatitis B, HIV Infections, Hepatitis C
Abstract

Background/objective: Refugees and migrants to the World Health Organization (WHO) European Region are disproportionately affected by infections, including tuberculosis (TB), human immunodeficiency virus (HIV) and hepatitis B and C (HBV/HCV) compared with the host population. There are inequities in the accessibility and quality of health services available to refugees and migrants in the Region. This has consequences for health outcomes and will ultimately impact the ability to meet Regional infection elimination targets., Methods: We reviewed academic and grey literature to identify national policies and guidelines for TB/HIV/HBV/HCV specific to refugees and migrants in the Member States of the WHO European Region and to identify: (i) evidence informing policy and (ii) barriers and facilitators to policy implementation., Results: Relatively few primary national policy/guideline documents were identified which related to refugees and migrants and TB [14 of 53 Member States (26%), HIV (n = 15, 28%) and HBV/HCV (n = 3, 6%)], which often did not align with the WHO recommendations, and for some countries, violated refugees' and migrants' human rights. We found extreme heterogeneity in the implementation of the WHO- and European Centre for Disease Prevention and Control (ECDC)-advocated policies and recommendations on the prevention, diagnosis, treatment and care of TB/HIV/HBV/HCV infection among migrants across the Member States of the WHO European Region.There is great heterogeneity in implementation of WHO- and ECDC-advocated policies on the prevention, diagnosis, treatment and care of TB/HIV/HBV/HCV infection in refugees and migrants across the Member States in the Region., Conclusion: More transparent and accessible reporting of national policies and guidelines are required, together with the evidence base upon which these policy decisions are based. Political engagement is essential to drive the changes in national legislation to ensure equitable and universal access to the diagnosis and care for infectious diseases., (© International Society of Travel Medicine 2022. Published by Oxford University Press.)

Published
2023
Full Text
View/download PDF

37. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.

Author

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, Alam M, Putri FA, Bastard M, Docteur W, Gottlieb G, Hewison C, Islam S, Khachatryan N, Kotrikadze T, Khan U, Kumsa A, Lecca L, Tassew YM, Melikyan N, Naing YY, Oyewusi L, Rich M, Wanjala S, Yedilbayev A, Huerga H, and Mitnick CD

Subjects
Antitubercular Agents therapeutic use, Humans, Oxazoles therapeutic use, Treatment Outcome, Mycobacterium tuberculosis, Nitroimidazoles therapeutic use, Tuberculosis, Multidrug-Resistant drug therapy
Abstract

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months. Clinical Trials Registration. NCT02754765., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results